Literature DB >> 31569143

Are there really only 2 kinds of people in the world? Evaluating the distribution of change from baseline in pain clinical trials.

Omar B Mbowe1, Jennifer S Gewandter2, Dennis C Turk3, Robert H Dworkin2,4,5,6, Michael P McDermott1,4,5,6.   

Abstract

It is often assumed that there are 2 types of pain patients: those who respond well to efficacious pain therapies and those who do not respond at all, with few people in the middle. This assumption is based on research that claims that changes in pain intensity have a bimodal distribution. The claim of bimodality has led to calls for a change in how pain clinical trials are designed and analyzed, eg, performing "responder" analyses instead of comparing group mean values to evaluate the treatment effect. We analyzed data from 4 clinical trials, 2 each of duloxetine and pregabalin, for chronic musculoskeletal and neuropathic pain conditions to critically examine the claim of bimodality of the distribution of change in pain intensity. We found that the improper construction of histograms, using unequal bin widths, was the principal flaw leading to the bimodality claim, along with the use of the oft-criticized baseline observation carried forward method for imputing missing data also serving as a contributing factor. Properly constructed histograms of absolute change in pain intensity using equal bin widths, combined with more principled methods for handling missing data, resulted in distributions that had a more unimodal appearance. Although our findings neither support nor refute the hypothesis that distinct populations of "responders" and "nonresponders" to pain interventions exist, the analyses presented in earlier work do not provide support for this hypothesis, nor for the recommendation that pain clinical trials prioritize "responder" analyses, a less efficient analysis strategy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31569143      PMCID: PMC6923574          DOI: 10.1097/j.pain.0000000000001708

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  23 in total

Review 1.  Stimulating the development of mechanism-based, individualized pain therapies.

Authors:  Janet Woodcock; James Witter; Raymond A Dionne
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

2.  Drugs for neuropathic pain.

Authors:  Eija Kalso; D J Aldington; R A Moore
Journal:  BMJ       Date:  2013-12-19

Review 3.  Twin Peaks? No Evidence of Bimodal Distribution of Outcomes in Clinical Trials of Nonsurgical Interventions for Spinal Pain: An Exploratory Analysis.

Authors:  Neil E O'Connell; Steven J Kamper; Matthew L Stevens; Qiang Li
Journal:  J Pain       Date:  2017-03-25       Impact factor: 5.820

4.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.

Authors:  John T Farrar; James P Young; Linda LaMoreaux; John L Werth; Michael R Poole
Journal:  Pain       Date:  2001-11       Impact factor: 6.961

Review 5.  Individual responder analyses for pain: does one pain scale fit all?

Authors:  Raymond A Dionne; Linda Bartoshuk; Jeffrey Mogil; James Witter
Journal:  Trends Pharmacol Sci       Date:  2005-03       Impact factor: 14.819

Review 6.  Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults.

Authors:  William Gibson; Benedict M Wand; Neil E O'Connell
Journal:  Cochrane Database Syst Rev       Date:  2017-09-14

7.  Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial.

Authors:  Amy S Chappell; Melissa J Ossanna; Hong Liu-Seifert; Smriti Iyengar; Vladimir Skljarevski; Linda Chunhong Li; Robert M Bennett; Harry Collins
Journal:  Pain       Date:  2009-07-21       Impact factor: 6.961

8.  Response to comments by Seaman et al. on "Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation," Journal of Biopharmaceutical Statistics 23:1352-1371.

Authors:  J R Carpenter; J H Roger; S Cro; M G Kenward
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

9.  The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study.

Authors:  A J Vickers
Journal:  BMC Med Res Methodol       Date:  2001-06-28       Impact factor: 4.615

10.  Duloxetine use in chronic painful conditions--individual patient data responder analysis.

Authors:  R A Moore; N Cai; V Skljarevski; T R Tölle
Journal:  Eur J Pain       Date:  2013-06-03       Impact factor: 3.931

View more
  2 in total

Review 1.  Topical clonidine for neuropathic pain in adults.

Authors:  Wojciech T Serednicki; Anna Wrzosek; Jaroslaw Woron; Jaroslaw Garlicki; Jan Dobrogowski; Joanna Jakowicka-Wordliczek; Jerzy Wordliczek; Renata Zajaczkowska
Journal:  Cochrane Database Syst Rev       Date:  2022-05-19

2.  Cutoff criteria for the placebo response: a cluster and machine learning analysis of placebo analgesia.

Authors:  Per M Aslaksen
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.